Becton, Dickinson and Company
BDX
Positions held
Your positionsBDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Becton, Dickinson and Company operates in a stable healthcare sector with a growing demand for medical instruments and supplies, positioning itself well against competitors.
- Revenue increased by 6% compared to the prior quarter, reaching $5.0 billion.
- Gross margin improved to 46.5%, up from 45.7% in the previous quarter.
- The company's earnings growth has declined significantly, with a -31.4% change indicating potential challenges in profitability.
- Net income for the most recent quarter was -$311 million, a stark contrast to the positive net income of $493 million in the previous quarter.
- The operating margin has been inconsistent, with a decrease from 14.0% in Q3 2025 to 12.6% in Q4 2025.
Fundamentals
| Market cap | $49.78B | Enterprise value | $65.88B | Trailing P/E | 42.50 | Forward P/E | 13.74 |
| PEG | 1.11 | Price / book | 2.04 | Beta | 0.28 | Dividend yield | 2.30% |
| Revenue growth | 5.4% | Earnings growth | -31.4% | Gross margin | 46.9% | Operating margin | 15.7% |
| Profit margin | 4.2% | ROE | 6.6% | ROA | 4.3% | Debt / equity | 0.69 |
| Current ratio | 0.87 | Free cash flow | $4.48B | Analyst recommendation | buy | Mean target | $194.08 |
| 52w high | $193.07 | 52w low | $127.59 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.0B | $4.7B | $5.3B | $5.9B | $4.7B | — |
| Op margin | 15.1% | 13.3% | 12.6% | 14.0% | 17.7% | — |
| Net income | $377M | -$311M | $382M | $493M | $574M | — |
| Gross margin | 46.5% | 45.7% | 45.9% | 47.5% | 47.3% | — |
| Gross profit | $2.3B | $2.2B | $2.4B | $2.8B | $2.2B | — |
| Operating income | $752M | $626M | $662M | $826M | $835M | — |
- Revenue +6% vs prior quarter ($5.0B vs $4.7B).
- Gross margin 46.5% (was 45.7% prior quarter).
- Operating margin expanded to 15.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $21.8B | $20.2B | $19.4B | $18.9B |
| Op margin | 13.7% | 14.2% | 12.5% | 13.1% |
| Net income | $1.7B | $1.7B | $1.5B | $1.8B |
| Gross margin | 45.4% | 45.2% | 42.2% | 44.9% |
| Gross profit | $9.9B | $9.1B | $8.2B | $8.5B |
| Operating income | $3.0B | $2.9B | $2.4B | $2.5B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
2026-10-09 · Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?
2026-10-08 · BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
2026-10-08 · Will BD’s US$19 Billion U.S. Manufacturing Push and Tariff Relief Change Becton Dickinson's (BDX) Narrative
2026-10-08 · BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
2026-10-08 · BD reports nine-month AGILITY trial data for Revello stent
2026-10-08 · BD reports nine-month AGILITY trial data for Revello stent
2026-10-07 · Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $210 From $180
2026-10-07 · BDX Expands U.S. Manufacturing With $19B Healthcare Investment
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target
2026-10-07 · BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
Price (daily)
Full chart · RSI · MACD · patterns